Senior Scientist, Vaccine Drug Product Development
AstraZeneca
Washington, District of Columbia
Michael Newton is a scientist within AstraZeneca's Biopharmaceutical Development department focusing on drug delivery and RNA drug product development. Since joining AstraZeneca in 2018, Michael has worked on the formulation and early-stage development of lipid nanoparticles (LNPs) encapsulating a variety of nucleic acids for therapeutic and vaccine applications, including mRNA. In his current role, Michael has led the development, scale-up, and tech transfer of mRNA-LNP drug products and related processes within the Vaccine Drug Product Development team as well as driven initiatives in mRNA-LNP process understanding and analytical method development efforts.
Michael holds a Master's degree in Chemical Engineering from the University of Washington, and a Bachelor’s degree in Chemical Engineering from the University of Utah.
Disclosure information not submitted.
Bridging the Gap: Developing Solutions for Efficient mRNA-LNP Process Tech Transfer
Monday, May 5, 2025
10:30 AM - 10:45 AM ET
Monday, May 5, 2025
10:45 AM - 11:00 AM ET